首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   16243篇
  免费   1122篇
  国内免费   65篇
耳鼻咽喉   348篇
儿科学   477篇
妇产科学   431篇
基础医学   2136篇
口腔科学   265篇
临床医学   1533篇
内科学   3003篇
皮肤病学   622篇
神经病学   1658篇
特种医学   1057篇
外科学   2709篇
综合类   164篇
一般理论   19篇
预防医学   850篇
眼科学   407篇
药学   772篇
中国医学   5篇
肿瘤学   974篇
  2022年   93篇
  2021年   203篇
  2020年   183篇
  2019年   195篇
  2018年   322篇
  2017年   248篇
  2016年   314篇
  2015年   302篇
  2014年   464篇
  2013年   567篇
  2012年   679篇
  2011年   721篇
  2010年   497篇
  2009年   501篇
  2008年   659篇
  2007年   744篇
  2006年   686篇
  2005年   672篇
  2004年   593篇
  2003年   569篇
  2002年   590篇
  2001年   534篇
  2000年   522篇
  1999年   483篇
  1998年   274篇
  1997年   284篇
  1996年   240篇
  1995年   213篇
  1994年   186篇
  1993年   166篇
  1992年   355篇
  1991年   334篇
  1990年   295篇
  1989年   339篇
  1988年   280篇
  1987年   249篇
  1986年   272篇
  1985年   245篇
  1984年   183篇
  1983年   144篇
  1982年   99篇
  1981年   105篇
  1979年   133篇
  1978年   106篇
  1977年   92篇
  1976年   91篇
  1975年   91篇
  1974年   104篇
  1973年   110篇
  1971年   103篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
The belief is widespread that studies are unethical if their sample size is not large enough to ensure adequate power. The authors examine how sample size influences the balance that determines the ethical acceptability of a study: the balance between the burdens that participants accept and the clinical or scientific value that a study can be expected to produce. The average projected burden per participant remains constant as the sample size increases, but the projected study value does not increase as rapidly as the sample size if it is assumed to be proportional to power or inversely proportional to confidence interval width. This implies that the value per participant declines as the sample size increases and that smaller studies therefore have more favorable ratios of projected value to participant burden. The ethical treatment of study participants therefore does not require consideration of whether study power is less than the conventional goal of 80% or 90%. Lower power does not make a study unethical. The analysis addresses only ethical acceptability, not optimality; large studies may be desirable for other than ethical reasons.  相似文献   
993.
Wolf G  Chen S  Ziyadeh FN 《Diabetes》2005,54(6):1626-1634
Nephropathy is a major complication of diabetes. Alterations of mesangial cells have traditionally been the focus of research in deciphering molecular mechanisms of diabetic nephropathy. Injury of podocytes, if recognized at all, has been considered a late consequence caused by increasing proteinuria rather than an event inciting diabetic nephropathy. However, recent biopsy studies in humans have provided evidence that podocytes are functionally and structurally injured very early in the natural history of diabetic nephropathy. The diabetic milieu, represented by hyperglycemia, nonenzymatically glycated proteins, and mechanical stress associated with hypertension, causes downregulation of nephrin, an important protein of the slit diaphragm with antiapoptotic signaling properties. The loss of nephrin leads to foot process effacement of podocytes and increased proteinuria. A key mediator of nephrin suppression is angiotensin II (ANG II), which can activate other cytokine pathways such as transforming growth factor-beta (TGF-beta) and vascular endothelial growth factor (VEGF) systems. TGF-beta1 causes an increase in mesangial matrix deposition and glomerular basement membrane (GBM) thickening and may promote podocyte apoptosis or detachment. As a result, the denuded GBM adheres to Bowman's capsule, initiating the development of glomerulosclerosis. VEGF is both produced by and acts upon the podocyte in an autocrine manner to modulate podocyte function, including the synthesis of GBM components. Through its effects on podocyte biology, glomerular hemodynamics, and capillary endothelial permeability, VEGF likely plays an important role in diabetic albuminuria. The mainstays of therapy, glycemic control and inhibition of ANG II, are key measures to prevent early podocyte injury and the subsequent development of diabetic nephropathy.  相似文献   
994.
995.
We delineate the methodology for constraint-induced movement therapy (CIMT) modified for children with hemiplegic cerebral palsy (CP) and describe important considerations that need to be made when testing this intervention in children. The resulting intervention evolved from piloting and testing it with 38 children with hemiplegic CP who were between the ages of 4 and 14 years. Thirty-seven successfully completed the treatment protocol. The intervention retains the 2 major elements of the adult CIMT (repetitive practice, shaping) and was constructed to be as child-friendly as possible. It involves restraining the noninvolved extremity with a sling and having the child engage in unimanual activities with the involved extremity 6 hours a day for 10 days (60 h). Specific activities are selected by considering joint movements with pronounced deficits and improvement of which interventionists believe have greatest potential. The activities are chosen to elicit repetitive practice and shaping. The intervention is conducted in groups of 2 to 3 children to provide social interaction, modeling, and encouragement. Each child is assigned to an interventionist to maintain at least a 1:1 ratio. CIMT can be modified to be child-friendly while maintaining all practice elements of the adult CIMT. The modified therapy is tolerated by most children. Further modifications will likely be required to hone in on the specific components of the intervention that are most effective before applying them to children who are most likely to benefit.  相似文献   
996.
Zusammenfassung Es wird die Arbeitsanweisung zur Anfertigung eines Schaumoxygenators für Zeitvolumina bis 400 ml/min gegeben. Die Sauerstoffsättigung des oxygenierten Blutes beträgt im Mittel 98%. Die Hämolyserate ist gering. Materialkosten und Zeitaufwand für die Anfertigung sind sehr niedrig.Die Untersuchungen wurden durch eine Sachbeihilfe der Deutschen Forschungsgemeinschaft in dankenswerter Weise unterstützt.  相似文献   
997.
998.
The rosette inhibition test for the detection of early pregnancy factor is described in detail. The extended methodology presented here represents the cumulative experience of three independent laboratories. Special reference is made to the effect on the assay of varying the conditions of rosette formation between lymphocytes and sheep red blood cells. Antilymphocyte sera prepared for use in the rosette inhibition test fell into three catagories: (i) with no rosette inhibiting activity, (ii) with rosette inhibiting activity which is not affected by the presence of EPF, and (iii) rosette inhibiting activity which is significantly increased in the presence of EPF. To date, this third reaction has been found to be a specific indication of the presence in serum of early pregnancy factor.  相似文献   
999.
Specific antisera reacting with B-L (Ia-like) antigens were prepared by reciprocal immunization of animals from the congeneic lines CB and CC. The resulting antisera were tested either in direct or indirect immunofluorescence tests and stained 10-16% of peripheral blood cells (PBL). Of the B-L+ cells, 90% were B cells and 8% were T cells. After in vitro stimulation of PBL with ConA, 58% were B-L+ and 91% of these were T cells. B and T cells were defined by means of rabbit antisera raised against bursa and thymus cells made specific by absorption with the relevant tissues. Antigens determined by anti-B-L antisera, rabbit anti-bursa (ABS) and rabbit anti-thymus (ATS) sera showed an independent distribution on the membrane of PBL. The tissue distribution of B-L+ cells, defined by means of allo-antisera and monoclonal antibodies, was studied by direct and indirect immunofluorescence on sections of skin, liver, kidney and brain. In all organs, in addition to B cells and a small number of, presumably activated, T cells, macrophages and dendritic cells were positive. Notably, glia cells in the brain were also shown to express B-L antigen.  相似文献   
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号